The lowest dose that does anything: is that a real question?

Asking directly, because I could not find a straight answer: The lowest dose that does anything: is that a real question?

I have read the maintained page on this and I still have a gap, so I am asking rather than guessing.

Context: retatrutide, 22 weeks in, currently at a dose I reached by the standard four-week steps. Everything below is my own record rather than anything a clinician told me.

The specific question is the one in the title. What I have already checked: the labelling summary on the relevant documentation page, the two most-linked topics in this subcategory, and my own notes from the last 10 weeks. What I could not find is whether the answer changes at higher doses or whether it is the same arithmetic throughout.

If the answer is "it depends", I would rather know what it depends on than be given a number.

The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The reasoning is pharmacological — e.g., "I will split the difference between steps" — but it is reasoning from theory, not from evidence.

A guess, clearly labelled as one.

Coming back to post #11, because the follow-up matters more than the original answer.

The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.

The part I am sure of is shorter than the part I have written.

Confirming post #47 from a second method, which matters more than confirming it from a second person.

Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.

This is the first time the answer has come with its own limits attached. Appreciated.

Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step.

Second-hand on lowest dose, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.

On post #87 — agreed on the reasoning, with one qualification.

The version of lowest dose that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.

Taking post #109 at face value and following it one step further.

The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat it as one.